ReGen takes CMI (collagen meniscus implant) to Italy with Xmedica deal
This article was originally published in Clinica
Executive Summary
In what signals its first step towards building an EU-wide distribution network, ReGen Biologics has appointed Xmedica, a private Milan-based company focused on tissue engineering products, as exclusive distributor of the ReGen collagen meniscus implant (CMI) in Italy. The deal, which runs through to 2007, also gives Xmedica a non-exclusive licence to market ReGen's SharpShooter tissue repair system. Financial details of the agreement were not disclosed.